No Data
Stifel Maintains Zymeworks(ZYME.US) With Buy Rating, Maintains Target Price $28
Zymeworks (ZYME) Receives a Buy From Stifel Nicolaus
Zymeworks Sets Strategic Milestones for 2025-2026 With Focus on Novel Therapeutics
Express News | Zymeworks Inc - Ind Applications for ZW209 and ZW1528 Expected in 2026
Express News | Zymeworks Inc - Ind Applications for ZW220 and ZW251 in Solid Tumors Expected in 2025
Zymeworks Expects $324M Cash Resources, Plus $25M Milestone, To Fund Operations Into 2H-2027